Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials

European Journal of Epidemiology

Volumn 25, Issue 1, 2010, Pages 29-35

  Bonovas, Stefanos ^a,b   Nikolopoulos, Georgios ^b   Filioussi, Kalitsa ^c   Peponi, Evangelia ^d   Bagos, Pantelis ^e   Sitaras, Nikolaos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Centre for Disease Control and Prevention   (Greece)

^c University Hospital of Zurich ^*  (Greece)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Chemoprevention; Melanoma; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN; MELANOMA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

ACYL COENZYME A; AGED; CHEMOPREVENTION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SKIN NEOPLASMS;

EID: 75049085880     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-009-9396-x     Document Type: Article

References (43)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009.
2. S Bonovas A Tsantes T Drosos NM Sitaras 2008 Cancer chemoprevention: a summary of the current evidence Anticancer Res 28 1857 1866 1:CAS:528: DC%2BD1cXos1yrs7s%3D 18630472
3. A Saito N Saito W Mol H Furukawa A Tsutsumida A Oyama M Sekido S Sasaki Y Yamamoto 2008 Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells Melanoma Res 18 85 94 10.1097/CMR.0b013e3282f60097 1:CAS:528:DC%2BD1cXjt1ertb0%3D 18337644
4. C Minichsdorfer M Hohenegger 2009 Autocrine amplification loop in statin-induced apoptosis of human melanoma cells Br J Pharmacol 157 1278 1290 10.1111/j.1476-5381.2009.00298.x 1:CAS:528:DC%2BD1MXhtVelt7fM 19563533
5. SA Glynn D O'Sullivan AJ Eustace M Clynes N O'Donovan 2008 The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells BMC Cancer 8 9 10.1186/1471-2407-8-9 18199328 (Pubitemid 351309029)
6. SO Francis MJ Mahlberg KR Johnson ME Ming RP Dellavalle 2006 Melanoma chemoprevention J Am Acad Dermatol 55 849 861 10.1016/j.jaad.2006.04.014 17052492 (Pubitemid 44556826)
7. MF Demierre PD Higgins SB Gruber E Hawk SM Lippman 2005 Statins and cancer prevention Nat Rev Cancer 5 930 942 10.1038/nrc1751 1:CAS:528: DC%2BD2MXht1ykurbL 16341084 (Pubitemid 41766782)
8. EA Collisson DC Carranza IY Chen MS Kolodney 2002 Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells J Invest Dermatol 119 1172 1176 10.1046/j.1523-1747.2002.19519.x 1:CAS:528:DC%2BD38XpslCrtLY%3D 12445208 (Pubitemid 35430495)
9. JP Jani S Specht N Stemmler K Blanock SV Singh V Gupta A Katoh 1993 Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis Invasion Metastasis 13 314 324 1:STN:280: DyaK2M7msVWiuw%3D%3D 7860224
10. S Greenland 1994 A critical look at some popular meta-analytic methods Am J Epidemiol 140 290 296 1:STN:280:DyaK2czgtlKltg%3D%3D 8030632
11. JD Emerson E Burdick DC Hoaglin 1990 An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials Control Clin Trials 11 339 352 10.1016/0197-2456(90)90175-2 1:STN:280:DyaK3M7ks1arsg%3D%3D 1963128
12. P Juni A Witschi R Bloch M Egger 1999 The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1054 1060 10.1001/jama.282.11.1054 1:STN:280:DyaK1MvitV2ntQ%3D%3D 10493204 (Pubitemid 29436453)
13. N Mantel W Haenszel 1959 Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 719 748 1:STN:280:DyaG1M%2FosVOhtQ%3D%3D 13655060
14. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 188 10.1016/0197-2456(86)90046-2 1:STN:280:DyaL2s7gsVamtA%3D%3D 3802833 (Pubitemid 17189972)
15. Bagos PG, Nikolopoulos GK. Mixed-effects poisson regression models for meta-analysis of follow-up studies with constant or varying durations. Int J Biostat. 2009;5:Article 21.
16. WG Cochran 1954 The combination of estimates from different experiments Biometrics 8 101 129 10.2307/3001666
17. JPT Higgins SG Thompson 2002 Quantifying heterogeneity in a meta-analysis Stat Med 21 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
18. JPT Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 557 560 10.1136/bmj.327.7414.557 12958120
19. CB Begg M Mazumdar 1994 Operating characteristics of a rank correlation test for publication bias Biometrics 50 1088 1101 10.2307/2533446 1:STN:280:DyaK2Mzgs1GrtQ%3D%3D 7786990
20. M Egger GD Smith M Schneider C Minder 1997 Bias in meta-analysis detected by a simple graphical test BMJ 315 629 634 1:STN:280:DyaK2svls1KjtA%3D%3D 9310563
21. DT Felson 1992 Bias in meta-analytic research J Clin Epidemiol 45 885 892 10.1016/0895-4356(92)90072-U 1:STN:280:DyaK38zisFOgtQ%3D%3D 1624971
22. A Tobias 1999 Assessing the influence of a single study in the meta-analysis estimate Stata Techn Bull 8 15 17
23. D Moher DJ Cook S Eastwood I Olkin D Rennie DF Stroup 1999 Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses Lancet 354 1896 1900 10.1016/S0140-6736(99)04149-5 1:STN:280:DC%2BD3c%2FkvFCgtQ%3D%3D 10584742
24. EA Stein A Corsini CR Gimpelewicz M Bortolini M Gil 2006 Fluvastatin treatment is not associated with an increased incidence of cancer Int J Clin Pract 60 1028 1034 10.1111/j.1742-1241.2006.01071.x 1:CAS:528:DC%2BD28XhtVOgurvL 16939542 (Pubitemid 44226738)
25. Heart Protection Study Collaborative Group 2005 The effects of cholesterol lowering with simvastatin on cause-specific mortality, on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial BMC Med 3 6 10.1186/1741-7015-3-6 (Pubitemid 41534989)
26. BG Stegmayr M Brännström S Bucht V Crougneau E Dimeny A Ekspong M Eriksson B Granroth KC Gröntoft H Hadimeri B Holmberg B Ingman B Isaksson G Johansson K Lindberger L Lundberg L Mikaelsson E Olausson B Persson H Stenlund AM Wikdahl Nediat Study Group 2005 Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study Scand J Urol Nephrol 39 489 497 10.1080/00365590500329304 1:CAS:528:DC%2BD2MXht1eltLbJ 18161210 (Pubitemid 41722032)
27. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico) 2000 Results of the low-dose (20 mg) pravastatin GISSI prevenzione trial in 4,271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1 810 820
28. IC Marschner D Colquhoun RJ Simes P Glasziou P Harris BB Singh D Friedlander H White P Thompson A Tonkin Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study 2001 Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with pravastatin in ischemic disease (LIPID) study J Am Coll Cardiol 38 56 63 10.1016/S0735-1097(01)01360-2 1:STN:280:DC%2BD3MzpvFGhsg%3D%3D 11451296 (Pubitemid 32613828)
29. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere A Langendorfer EA Stein W Kruyer AM Gotto Jr 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/texas coronary atherosclerosis prevention study JAMA 279 1615 1622 10.1001/jama.279.20.1615 1:STN:280:DyaK1c3ntl2qsw%3D%3D 9613910 (Pubitemid 28248586)
30. FM Sacks MA Pfeffer LA Moye JL Rouleau JD Rutherford TG Cole L Brown JW Warnica JM Arnold CC Wun BR Davis E Braunwald 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1001 1009 10.1056/NEJM199610033351401 1:CAS:528:DyaK28XmsFWls7c%3D 8801446 (Pubitemid 26338729)
31. J Shepherd SM Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group N Engl J Med 333 1301 1307 10.1056/NEJM199511163332001 1:CAS:528: DyaK28Xhslemsw%3D%3D 7566020
32. Scandinavian Simvastatin Survival Study Group 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S) Lancet 344 1383 1389
33. SR Freeman AL Drake LF Heilig M Graber K McNealy LM Schilling RP Dellavalle 2006 Statins, fibrates, and melanoma risk: a systematic review and meta-analysis J Natl Cancer Inst 98 1538 1546 1:CAS:528:DC%2BD28XhtFyqt7%2FI 17077356
34. S Bonovas K Filioussi N Tsavaris NM Sitaras 2006 Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials J Clin Oncol 24 4808 4817 10.1200/JCO.2006.06.3560 1:CAS:528:DC%2BD28Xht1eiu73M 17001070 (Pubitemid 46655612)
35. S Bonovas K Filioussi CS Flordellis NM Sitaras 2007 Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million subjects J Clin Oncol 25 3462 3468 10.1200/JCO.2007.10.8936 17687150 (Pubitemid 47310884)
36. S Bonovas K Filioussi NM Sitaras 2008 Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies Int J Cancer 123 899 904 10.1002/ijc.23550 1:CAS:528: DC%2BD1cXovFWmu74%3D 18491405 (Pubitemid 352032419)
37. S Bonovas K Filioussi NM Sitaras 2008 Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies Am J Gastroenterol 103 2646 2651 10.1111/j.1572-0241.2008.02051.x 1:CAS:528:DC%2BD1cXhtlaksLnI 18684187
38. S Bonovas K Filioussi A Tsantes NM Sitaras 2007 Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies Br J Clin Pharmacol 64 255 262 10.1111/j.1365-2125.2007.02959.x 1:CAS:528:DC%2BD2sXhtFKis7%2FJ 17578480 (Pubitemid 47283870)
39. S Bonovas K Filioussi N Tsavaris NM Sitaras 2005 Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies J Clin Oncol 23 8606 8612 10.1200/JCO.2005.02.7045 16260694 (Pubitemid 46211502)
40. S Bonovas NM Sitaras 2009 Statins and cancer risk: a confounded association Gastroenterology 137 740 10.1053/j.gastro.2009.02.088 19563833
41. K Dale C Coleman N Henyan J Kluger C White 2006 Statins and cancer risk: a meta-analysis JAMA 295 74 80 10.1001/jama.295.1.74 1:CAS:528: DC%2BD28XhtlOgsQ%3D%3D 16391219 (Pubitemid 43042692)
42. Dellavalle R, Drake A, Graber M, Heilig L, Hester E, Johnson K, McNealy K, Schilling L. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev. 2005;CD003697.
43. DS Rigel JA Carucci 2000 Malignant melanoma: prevention, early detection, and treatment in the 21st century CA Cancer J Clin 50 215 236 10.3322/canjclin.50.4.215 1:STN:280:DC%2BD3cvlsFOjtg%3D%3D 10986965